drugset / Trial / NCT06209671
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Phase 1
Unknown
12 enrolled
Beijing Immunochina Medical Science & Technology Co., Ltd.
Peking University People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety, tolerability, and pharmacokinetic profile of INS19 CAR-T cells for the treatment of patients with relapsed or refractory acute B lymphoblastic leukemia
Timeline
- Start
- 2024-01-15
- Primary completion
- 2025-01-15
- Completion
- 2026-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INS19 CAR-T Cells | Unknown | 1e+07 cells | — |
| Subject | INS19 CAR-T Cells | Unknown | 2e+07 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |